Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 18/20 | 1.00 |
| ▸ | MARK3 | P27448 | 4/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 3/20 | 1.00 |
| ▸ | MARK4 | Q96L34 | 3/20 | 1.00 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 1.00 |
| ▸ | ULK1 | O75385 | 2/20 | 1.00 |
| ▸ | ULK2 | Q8IYT8 | 2/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 1/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 1/20 | 1.00 |
| ▸ | SIK1 | P57059 | 1/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 1.00 |
| ▸ | MELK | Q14680 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 1.00 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 1.00 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 1.00 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 0.72 |
| ▸ | BRSK2 | Q8IWQ3 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29464028 | 1.00 | TBK1 (1.00) | TBK1MARK3IKBKEMARK4STK17A | |
| SCHEMBL13431845 | 1.00 | TBK1 (1.00) | TBK1MARK3IKBKEMARK4STK17A | |
| Hydrochloric Acid SCHEMBL30503011 | 0.99 | TBK1 (0.98) | TBK1MARK3IKBKEMARK4STK17A | |
| Hydrochloric Acid SCHEMBL26091529 | 0.99 | TBK1 (0.98) | TBK1MARK3IKBKEMARK4STK17A | |
| Hydrochloric Acid SCHEMBL30409158 | 0.99 | TBK1 (0.98) | TBK1MARK3IKBKEMARK4STK17A | |
| SCHEMBL13431885 | 0.94 | TBK1 (0.88) | TBK1MARK3IKBKEMARK4STK17A | |
| SCHEMBL13431884 | 0.93 | TBK1 (0.87) | TBK1MARK3IKBKEMARK4STK17A | |
| SCHEMBL13431871 | 0.91 | TBK1 (0.84) | TBK1MARK3IKBKEMARK4STK17A | |
| SCHEMBL13431886 | 0.90 | TBK1 (0.81) | TBK1MARK3IKBKEMARK4STK17A | |
| SCHEMBL13431797 | 0.88 | TBK1 (1.00) | TBK1MARK3IKBKEMARK4STK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250313862-A1 | INHIBITION OF GENOTOXIC STRESS TO IMPROVE T CELL ENGINEERING | GENENTECH INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250283110-A1 | METHODS AND COMPOSITIONS FOR TRANSDUCTION OF NK CELLS | ST JUDE CHILDRENS RES HOSPITAL INC (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2023178276-A1 | TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA WITH MIRDAMETINIB | SpringWorks Therapeutics Inc. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2022251584-A1 | METHODS AND COMPOSITIONS FOR TRANSDUCTION OF NK CELLS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313862-A1 | INHIBITION OF GENOTOXIC STRESS TO IMPROVE T CELL ENGINEERING | STING1, CGAS, NFATC1 | TBK1 38/4885MARK3 4387/4885IKBKE 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.